US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

24.43

-2.5400-9.42%

Post-market: 24.900.4700+1.92%17:06 EDT

Volume:79.82K

Turnover:1.98M

Market Cap:274.14M

PE:-3.12

High:26.39

Open:25.00

Low:24.00

Close:26.97

Loading ...

Overview Company News Filings

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank

Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027

Palvella Therapeutics Q4 EPS $(7.83) Misses $(3.02) Estimate

Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)

Press Release: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Calendar of U.S. Earnings Expected in the Week Ahead

Palvella Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects

Palvella Therapeutics Initiated at Buy by Stifel

Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target

MT Newswires Live

Palvella Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $45

THOMSON REUTERS

Palvella Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $45

THOMSON REUTERS

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well

Simply Wall St.

Palvella Therapeutics Initiated at Sector Outperform by Scotiabank

Palvella Therapeutics initiated with an Outperform at Scotiabank

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":24.43,"timestamp":1743710400000,"preClose":26.97,"halted":0,"volume":79818,"hourTrading":{"tag":"盘后","latestPrice":24.9,"preClose":24.43,"latestTime":"17:06 EDT","volume":3,"amount":73.759998,"timestamp":1743714382387},"delay":0,"floatShares":6497315,"shares":11221307,"eps":-7.832217,"marketStatus":"Post-Market Trading","change":-2.54,"latestTime":"04-03 19:15:48 EDT","open":25,"high":26.39,"low":24,"amount":1981834.485924,"amplitude":0.088617,"askPrice":28.6,"askSize":100,"bidPrice":22,"bidSize":975,"shortable":0,"etf":0,"ttmEps":-7.832217,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743724800000},"marketStatusCode":4,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":26.97,"preHourTrading":{"tag":"盘前","latestPrice":25.59,"preClose":26.97,"latestTime":"09:27 EDT","volume":806,"amount":20702.959523999998,"timestamp":1743686828388},"postHourTrading":{"tag":"盘后","latestPrice":24.9,"preClose":24.43,"latestTime":"17:06 EDT","volume":3,"amount":73.759998,"timestamp":1743714382387},"volumeRatio":1.043206,"impliedVol":0.4687,"impliedVolPercentile":0.5217},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":6497315,"roa":"-18.39%","roe":"-59.37%","lyrEps":-7.832217,"volumeRatio":1.043206,"shares":11221307,"dividePrice":0,"high":26.39,"amplitude":0.088617,"preClose":26.97,"low":24,"week52Low":6.2,"pbRate":"4.38","week52High":29.27,"institutionHeld":0,"latestPrice":24.43,"committee":0.813953,"eps":-7.832217,"divideRate":0,"volume":79818,"delay":0,"ttmEps":-7.832217,"open":25,"prevYearClose":12,"prevWeekClose":28.1,"prevMonthClose":27.99,"prevQuarterClose":27.99,"fiveDayClose":27.76,"twentyDayClose":23.94,"sixtyDayClose":14.755},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524118947","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118947?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:05 ET (12:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2524194968","title":"Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194968?lang=en_us&edition=fundamental","pubTime":"2025-04-01 18:56","pubTimestamp":1743504973,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report) today and set a price target of $50.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2524745163","title":"Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524745163","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524745163?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:01","pubTimestamp":1743490904,"startTime":"0","endTime":"0","summary":"Cash and Cash Equivalents: $83.6 million as of December 31, 2024.Cash Runway: Expected to extend into the second half of 2027.Research and Development Expenses: $8.2 million for the full-year 2024, compared to $8.8 million in 2023.General and Administrative Expenses: $5.9 million for the full-year 2024, compared to $3.1 million in 2023.Net Loss: $17.4 million or $7.83 per diluted share for the full-year 2024.Net Income : $17.9 million or $2.17 per diluted share for 2023.Projected Cash Spend for 2025: Approximately $30 million.Projected R&D Spend for 2025: $18 million to $20 million.Projected G&A Spend for 2025: $10 million to $12 million.Expected Year-End 2025 Cash Balance: At least $55 million.GuruFocus has detected 3 Warning Signs with ITXXF.Palvella Therapeutics Inc  is leveraging the 505 regulatory pathway for its NDA submission, which could streamline the drug review process and expedite approval.Palvella Therapeutics Inc  reported a net loss of $17.4 million for the full-year 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-inc-pvla-q4-070144507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PVLA"],"gpt_icon":0},{"id":"2523422299","title":"Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523422299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523422299?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:31","pubTimestamp":1743427908,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryPalvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of $2.72 per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523908945","title":"CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2523908945","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523908945?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:07","pubTimestamp":1743422863,"startTime":"0","endTime":"0","summary":"CORRECTION: Palvella Therapeutics FY24 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44559811/correction-palvella-therapeutics-fy24-gaap-eps-7-83-misses-2-10-estimate-cash-balance-of-83-6m-expe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523198948","title":"Palvella Therapeutics Q4 EPS $(7.83) Misses $(3.02) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523198948","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523198948?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743421019,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(7.83) per share which missed the analyst consensus estimate of $(3.02) by 159.27 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44558839/palvella-therapeutics-q4-eps-7-83-misses-3-02-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2523943353","title":"Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523943353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523943353?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:36","pubTimestamp":1743421017,"startTime":"0","endTime":"0","summary":"“2024 was marked by significant progress towards achieving our vision of becoming the leading rare disease biopharmaceutical company focused on ser...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-fy24-eps-7-83-consensus-3-01?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-reports-fy24-eps-7-83-consensus-3-01?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2523194839","title":"Press Release: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523194839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523194839?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:30","pubTimestamp":1743420600,"startTime":"0","endTime":"0","summary":"Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases. Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN 3.9% rapamycin anhydrous gel  for the treatment of microcystic lymphatic malformations , on track for the first quarter of 2026. Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN rapamycin for the treatment of cutaneous venous malformations , on track for the fourth quarter of 2025. Planned QTORIN pipeline expansion in second half of 2025. Cash and cash equivalents of over $83 million as of December 31, 2024 expected to fund operations into the second half of 2027. Mr. Kaupinen continued, \"In addition to these two initial indications for QTO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4139","BK4007","BK4585","BK4588","PVLA","BK4099","03160","LU1559883803.SGD","LGND","LU0566484027.USD","BK4604","TM"],"gpt_icon":0},{"id":"2523915166","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2523915166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523915166?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4178","PROK","BK4023","BHST","MSM","TTGT","UNF","LNZA","GWH","NNOX","BK4200","BW","LOAR","PENG","PRGS","AYI","PVLA","CAG","RANI","RH","APOG","BK4584","LNN","REKR","LPRO","WPRT","SGML","ANGO","RDUS","FTCI","BK4007","BK4524","CELC","LW","FC","BLRX","SPIR","CUK","AMC","DARE","SPWH","BK4141","NCNO","SLP","LU0054578231.USD","BK4086","BK4167","PVH","OMER"],"gpt_icon":0},{"id":"2522537579","title":"Palvella Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537579?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:40","pubTimestamp":1743165606,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to show a fall in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB0XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSAT","ATAI","FBIO","FTCI","UNCY","BHST","WBA","SPWH","PENG","WKSP","SLRN","AFMD","RLMD","SGML","PVLA","PRGS","CALC","LNZA","NCNO","CRDL","RANI","CELC","ANGO","KYTX","SDST","NNOX","NUTX","BW","TLSI","REKR","FC","GWH","IKT","LULU","DARE","CLSD","SKYH","PVH","BRZE","GEVO","BCAB","GOVX","WGO","BLRX","EDAP","FEMY","ADCT","INMB","MDAI","INR"],"gpt_icon":0},{"id":"2522335502","title":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335502?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:40","pubTimestamp":1743010809,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays,B. Riley, CarMaxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL6N3Q90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHWY","LU0654597011.USD","SURG","IE00B29SXK94.USD","BK4127","PVLA","ULTA","ALNY","VVX","IE00B894F039.SGD","RILY","LU1023059063.AUD","BK4547","LU0054578231.USD","LU0256863811.USD","EOG","LU0823414551.USD","DLTR","KMX","WING","LU0075056555.USD","FCX","LU0203345920.USD","WVE","CTAS","BBIO","LU2506952170.USD","SG9999002232.USD","GWRS","AEP","LU0980610538.SGD","EXEL","COCO","LU2294711713.HKD","SARO","JKS","SCCO","CVX","LU0050427557.USD","LU1582987597.SGD","LU0266512127.USD","BK4563","VRT","COTY","HUMA","PSX","XOM"],"gpt_icon":1},{"id":"2522385306","title":"BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2522385306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522385306?lang=en_us&edition=fundamental","pubTime":"2025-03-26 22:53","pubTimestamp":1743000784,"startTime":"0","endTime":"0","summary":"BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects** Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O  with \"buy\" rating and $45 PT** New PT re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL3N3PJ1LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2522876430","title":"Palvella Therapeutics Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2522876430","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522876430?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:36","pubTimestamp":1742988960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 07:36 ET (11:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4139","PVLA","SF"],"gpt_icon":0},{"id":"2522875588","title":"Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2522875588","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522875588?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:22","pubTimestamp":1742988171,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $42.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SF","PVLA"],"gpt_icon":0},{"id":"2522822296","title":"Palvella Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2522822296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522822296?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:40","pubTimestamp":1742985644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90SO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2522736055","title":"Palvella Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2522736055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522736055?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:01","pubTimestamp":1742871684,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2519092223","title":"Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well","url":"https://stock-news.laohu8.com/highlight/detail?id=2519092223","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519092223?lang=en_us&edition=fundamental","pubTime":"2025-03-16 22:20","pubTimestamp":1742134849,"startTime":"0","endTime":"0","summary":"Significant control over Palvella Therapeutics by individual investors implies that the general public has more power to influence management and governance-related decisions. A look at the shareholders of Palvella Therapeutics, Inc.  can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 41% ownership. In other words, the group stands to gain the most  from their investment into the company.While individual investors were the group that benefitted the most from last week’s US$33m market cap gain, insiders too had a 18% share in those profits.Let's delve deeper into each type of owner of Palvella Therapeutics, beginning with the chart below.What Does The Institutional Ownership Tell Us About Palvella Therapeutics?Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/individual-investors-hold-41-palvella-142049099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","QLD","TQQQ","USAW.SI","TSYW.SI",".IXIC","BK4588","IE00B3QW5Z07.USD","MNQmain","IE00BKPKM429.USD","LU2095319765.USD","SQQQ","NDAQ","PVLA","BK4112","USJW.SI","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","PSQ","NVIW.SI","LU2210149790.SGD","QID","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2517646924","title":"Palvella Therapeutics Initiated at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2517646924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517646924?lang=en_us&edition=fundamental","pubTime":"2025-03-08 06:39","pubTimestamp":1741387140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 17:39 ET (22:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2517818664","title":"Palvella Therapeutics initiated with an Outperform at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2517818664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517818664?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:55","pubTimestamp":1741348542,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $50 price target. The firm says Pal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-outperform-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-outperform-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95},{"market":"US","date":"2024-04-23","symbol":"PVLA","defaultRemindTime":1713879000000,"type":"split","dateTimestamp":1713844800000,"forFactor":80,"toFactor":1,"ratio":80}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1742961600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-04-02","current":-15.183586,"percent":0,"low":-15.183586,"twenty":20.817306,"median":28.371332,"eighty":43.469842,"high":46.119317,"avg":29.385721,"sd":10.926182,"marketCap":264710632},"quantilePoints":[{"date":"2025-01-03","current":19.083855,"twenty":19.083855,"median":19.083855,"eighty":19.083855,"marketCap":134655684},{"date":"2025-01-10","current":22.662078,"twenty":19.083855,"median":20.077806,"eighty":23.120091,"marketCap":159903624},{"date":"2025-01-17","current":21.024047,"twenty":19.083855,"median":21.024047,"eighty":22.483962,"marketCap":148345678},{"date":"2025-01-24","current":20.658273,"twenty":19.395558,"median":20.960435,"eighty":22.003685,"marketCap":145764777},{"date":"2025-01-31","current":21.469337,"twenty":19.914003,"median":20.93658,"eighty":21.408905,"marketCap":151487644},{"date":"2025-02-07","current":23.854819,"twenty":20.19708,"median":20.960435,"eighty":22.191343,"marketCap":168319605},{"date":"2025-02-14","current":31.806426,"twenty":20.537409,"median":21.047902,"eighty":23.471552,"marketCap":224426140},{"date":"2025-02-21","current":30.216104,"twenty":20.626467,"median":21.159225,"eighty":24.999851,"marketCap":213204833},{"date":"2025-02-28","current":29.977556,"twenty":20.64237,"median":22.089563,"eighty":29.977556,"marketCap":211521636},{"date":"2025-03-07","current":38.072292,"twenty":20.658273,"median":23.043756,"eighty":30.804523,"marketCap":268638089},{"date":"2025-03-14","current":43.224933,"twenty":20.674177,"median":23.473142,"eighty":31.806426,"marketCap":304995124},{"date":"2025-03-21","current":43.622513,"twenty":20.674177,"median":24.864674,"eighty":35.527777,"marketCap":307800451},{"date":"2025-03-28","current":44.147319,"twenty":20.912725,"median":26.844623,"eighty":43.224933,"marketCap":311503482},{"date":"2025-04-02","current":-15.183586,"twenty":20.817306,"median":28.371332,"eighty":43.469842,"marketCap":264710632}],"updateTime":1743706407885}}}